NEUP 20-F DEF-14A Report June 30, 2023

NEUPHORIA THERAPEUTICS INC.

10-Ks,20-Fs and 10-Qs

10-Q	Quarter ended Sept. 30, 2025
10-K	Fiscal year ended June 30, 2025
10-Q	Quarter ended March 31, 2025
10-Q	Quarter ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-K	Fiscal year ended June 30, 2024
20-F	Fiscal year ended June 30, 2023
20-F	Fiscal year ended June 30, 2022

PROXIES

DEF 14A	Filed on Dec. 9, 2025
DEF 14A	Filed on Dec. 11, 2024
DEF 14A	Filed on Nov. 12, 2024

Name: BIONOMICS LIMITED/FI CIK: 1191070 Filing Type: 20-F/A Report Date: 2023-06-30 Download URL: https://www.sec.gov/Archives/edgar/data/1191070/000095017024004818/bnox-20230630.htm

TABLE OF CONTENTS

Part I: Gender Identity Part Ii: Demographic Background Item 7. Major Shareholders and Related Party Transactions Item 7. Majo Item 8. Financial Information Item 8. Financia Item 9. The Offer and Listing Item 9. Th Item 10. Additional Information Item 10. Addi Item 11. Quantitative and Qualitative Disclosures About Market Risk Item 11. Quantitative Item 12. Description Of Securities Other Than Equity Securities Item 12. Description Of Secu Part II Item 13. Defaults, Dividend Arrearages and Delinquencies Item 13. Defaults Item 14. Material Modifications To The Rights Of Security Holders and Use Of Proceeds Item 14. Material Modifica Item 15. Controls and Procedures Item 15. Controls A Item 16A. Audit Committee Financial Expert Item 16A. Audit Com Item 16B. Code Of Ethics Item 16B. Code Item 16C. Principal Accounting Fees and Services Item 16C. Principal Ac Item 16D. Exemptions From The Listing Standards For Audit Committees Item 16D. Exemptions Fr Item 16E. Purchases Of Equity Securities By The Issuer and Affiliated Purchasers Item 16E. Purchases Of Equity Item 16F. Change in Registrant S Certifying Accountant Item 16F. Change in Reg Item 16G. Corporate Governance Item 16G. Corporat Item 16H. Mine Safety Disclosure Item 16H. Mine Safety Item 16I. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections Item 16I. Disclosure Regar Part III Item 17. Financial Statements Item 17. Fina Item 18. Financial Statements Item 18. Financial Item 19. Exhibits Item 19. Ex Note 1: General Information Note 1: General Info Note 2: Summary Of Significant Accounting Policies Note 3: Critical Accounting Estimates and Judgements Note 4: Segment Information Note 5: Revenue, Other Income and Other Gains and Losses Note 6: Expenses Relating To Continuing Operations Note 7: Income Taxes Relating To Continuing Operations Note 8: Cash and Cash Equivalents Note 9: Other Financial Assets Note 10: Trade and Other Receivables Note 11: Other Assets 2023a$ 2022a$ Current Prepayments 1,202,826 1,461,078 Accrued Income 388 190 1,203,214 1,461,268 Note 11: Other Assets Note 12: Subsidiaries Note 13: Property, Plant and Equipment Note 14: Right-of-use Assets Note 15: Goodwill Note 16: Other Intangible Assets Note 16: Othe Note 17: Trade and Other Payables Note 18: Lease Liabilities Note 19: Provisions 2023a$ 2022a$ Current Employee Benefits 457,017 409,320 Non-current Employee Benefits 22,398 10,460 Note 19: Provisions Note 20: Issued Capital Note 21: Reserves Note 22: Financial Instruments Note 23: Key Management Personnel Compensation Note 24: Commitments For Expenditure Note 25: Remuneration Of Auditors Note 26: Cash Flow Information Note 27: Loss Per Share Note 28: Related Party Transactions Note 29: Contingent Consideration Note 30: Contingent Liabilities Note 31: Events Occurring After Reporting Date

Exhibits

NEUP 20-F Report ended June 30, 2023

Exhibits